Improvement of fatigue in generalised myasthenia gravis with zilucoplan
Journal of Neurology · 2024-05 · 271 (5) · 2758-2767
DOI: 10.1007/s00415-024-12209-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Neurology, online erschienen am 24.02.2024. Verfasst von Michael D Weiss und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Washington Medical Center, Seattle, WA, USA. mdweiss@uw.edu. Hauptthemen laut MEDLINE: Myasthenia Gravis, Fatigue. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Background
Fatigue is a debilitating symptom of myasthenia gravis (MG). The impact of fatigue on MG can be assessed by Quality of Life in Neurological Disorders (Neuro-QoL) Short Form Fatigue scale. Transformation of raw Neuro-QoL fatigue scores to T-scores is a known approach for facilitating clinical interpretation of clinically meaningful and fatigue severity thresholds.
Methods
In the Phase 3, double-blind, placebo-controlled RAISE study (NCT04115293), adults with acetylcholine receptor autoantibody-positive generalised MG (MG Foundation of America Disease Class II–IV) were randomised 1:1 to daily subcutaneous zilucoplan 0.3 mg/kg or placebo for 12 weeks. Patients completing RAISE could opt to receive zilucoplan 0.3 mg/kg in an ongoing, open-label extension study, RAISE-XT (NCT04225871). In this post-hoc analysis, we evaluated the long-term effect of zilucoplan on fatigue in RAISE patients who entered RAISE-XT. We report change in Neuro-QoL Short Form Fatigue T-scores and fatigue severity levels from RAISE baseline to Week 60.
Results
Mean Neuro-QoL Short Form Fatigue T-scores improved from baseline to Week 12 in the zilucoplan group ( n = 86) with a clinically meaningful difference versus placebo ( n = 88; least squares mean difference: − 3.61 (nominal p -value = 0.0060]), and these improvements continued further to Week 60. At Week 12, more patients on zilucoplan ( n = 34, 47.2%) experienced improvements in ≥ 1 fatigue severity level from baseline versus placebo ( n = 23, 28.4%; p = 0.017). At Week 60, most ( n = 55, 65.5%) patients had mild fatigue or none.
Conclusion
Treatment with zilucoplan demonstrated statistical and clinically meaningful improvements in fatigue scores and severity versus placebo during RAISE, which were sustained to Week 60 in RAISE-XT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, University of Washington Medical Center, Seattle, WA, USA. mdweiss@uw.edu.
- Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
- Department of Neurology, Oslo University Hospital, Oslo, Norway.
- Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
- UCB Pharma, Brussels, Belgium.
Förderung
- UCB Pharma
Zitieren
APA
Weiss, M. D., Freimer, M., Leite, M. I., Maniaol, A., Utsugisawa, K., Bloemers, J., Boroojerdi, B., Howard, E., Savic, N., & Howard, J. F. (2024). Improvement of fatigue in generalised myasthenia gravis with zilucoplan. Journal of Neurology, 271(5), 2758-2767. https://doi.org/10.1007/s00415-024-12209-3
Vancouver
Weiss MD, Freimer M, Leite MI, Maniaol A, Utsugisawa K, Bloemers J, et al. Improvement of fatigue in generalised myasthenia gravis with zilucoplan. Journal of Neurology. 2024;271(5):2758-2767. doi:10.1007/s00415-024-12209-3
BibTeX
@article{Weiss2024,
author = {Weiss, Michael D and Freimer, Miriam and Leite, M Isabel and Maniaol, Angelina and Utsugisawa, Kimiaki and Bloemers, Jos and Boroojerdi, Babak and Howard, Emily and Savic, Natasa and Howard, James F},
title = {Improvement of fatigue in generalised myasthenia gravis with zilucoplan},
journal = {Journal of Neurology},
year = {2024},
volume = {271},
number = {5},
pages = {2758--2767},
doi = {10.1007/s00415-024-12209-3}
}
EUVIMED